Treace publishes four-year bunion surgery study results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- BofA raises hyperscaler AI capex outlook to $3.6tn through 2028
Treace Announces Peer-Reviewed Publication of Four-Year Results of the ALIGN3D™ Lapiplasty® Multicenter Prospective Clinical Study
August 5, 2025 4:05 PM EDTPONTE VEDRA, Fla., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (Treace or the Company) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced the peer-reviewed publication of the four-year interim results from its ALIGN3D multicenter prospective study demonstrating positive clinical and radiographic outcomes of the Lapiplasty® Procedure in the Journal of Foot & Ankle Surgery.
The published results entitled, Four-Year Outcomes Following Triplanar Tarsometatarsal Arthrodesis with Early Weightbearing for Hallux Valgus: A Multicenter Prospective Study... More
